1. Bank of America Merrill LynchHealth Care ConferenceDoug ManionSenior Vice President,Virology, Neuroscience and JapanMay 17, 2012 1

2. Forward-Looking Information During this meeting, we will make statements about the Companys future plans and prospects that constitute forward- looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the companys most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. NOT FOR PRODUCT PROMOTIONAL USE2 3. Data as of December 31, 2011 NME Development PortfolioExploratory Development *FullMarketed ProductDevelopment ^ Development EGFR/IGFRNS5A SecondTandem Adnectin PEG-FGF21 LXR ModulatorsGenerationBrivanibYERVOYTM NULOJIX Pegdinetanib 11HSDNS5B Site 1(VEGF R-2 Adnectin)PCSK9 Adnectin InhibitorSPRYCEL ELIQUISTM ** InhibitorsNecitumumab CCR2 / 5 -7 NicotinicAnti-CD70 ADCTGR5 Agonist Antagonists Agonist ERBITUXBARACLUDE Elotuzumab JAK2 Inhibitor FGF21-PKE IKACh Inhibitors A ModulatorIXEMPRA REYATAZ AdnectinTriple ReuptakeIGF-1RIKur Antagonists Inhibitors Dapagliflozin SUSTIVA / Antagonist GPR119 Agonists ORENCIA ATRIPLAMicrotubule CCR1PeginterferonONGLYZA /SMO Antagonist StabilizerDaclatasvirABILIFYAntagonists lambda-1a (NS5A Inhibitor)KOMBIGLYZETM XRAvagacestatAsunaprevir(Gamma SecretaseIL-21Anti-IP10(NS3 Inhibitor)Inhibitor)Anti-KIR NS5B Inhibitor GABA/Nicotinic Anti-CD28Modulator Urelumab HIV AttachmentAnti-IL6 InhibitorCGRP Antagonist (Anti-CD137)Notch Inhibitors IL-23 Adnectin Anti-PD-L1Anti-PD1 Anti-IL31 NRT Inhibitor HIV MaturationAnti-CXCR4Anti-CD40LInhibitor* Post discovery through Phase IINS5B Primer Grip^ Registrational program Anti-LAG3LPA1 AntagonistInhibitor Approved in at least one major marketONCMETIMMCV VIR NS**ELIQUIS is approved for VTE Prevention in the EU NOT FOR PRODUCT PROMOTIONAL USE3 4. HCV Area of High Unmet NeedHistoric Standard of Current Standard ofBMS GoalCareCare(